← Leaderboards
Alexander Egbe
Mayo Clinic Rochester
$8,108,397
Attributed
$8,108,397
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.9M · FY2018–25$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,108,397 · 4
By mechanism
R01$7,415,297 · 3
K23$693,100 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Cohort”
- Leonard Freedman · Leidos Biomedical Research, Inc.$70,225,348
- April Brinkoetter · Hungry Heart Media, Inc.$57,302,265
- Julie Ake · National Institute Of Allergy And Infectious Diseases$52,642,120
- Sarah Fortune · Harvard School Of Public Health$51,119,645
- Scott Hensley · University Of Pennsylvania$47,346,110
- Susan M Landau · University Of California Berkeley$47,252,026
Research focus
CohortMorbidity - Disease RateInnovationHealth Care CostsPublic HealthPreventChronicHemodynamicsMissionIndexingPreventionMortalityNovel TherapeuticsDisabilityPrematureImpairmentFutureBurden Of IllnessAerobicLifeCardiovascular SystemCessation Of LifeOxygen ConsumptionTreatment Strategy
Grant awards (16)
Clinical benefits and mechanism of action of angiotensin-II receptor blocker on Cardiovascular remodeling in patients with repaired coarctation of aorta$665,332
R01 · FY2025 · HL · contact PI
Mechanisms of Clinical and Hemodynamic Response to Pulmonary Vasodilator Therapy in Fontan physiology$635,550
R01 · FY2025 · HL · contact PI
Pathophysiologic Mechanism for Arrhythmias and Impaired Aerobic Capacity in Tetralogy of Fallot$575,323
R01 · FY2025 · HL · contact PI
Clinical benefits and mechanism of action of angiotensin-II receptor blocker on Cardiovascular remodeling in patients with repaired coarctation of aorta$652,072
R01 · FY2024 · HL · contact PI
Mechanisms of Clinical and Hemodynamic Response to Pulmonary Vasodilator Therapy in Fontan physiology$622,841
R01 · FY2024 · HL · contact PI
Pathophysiologic Mechanism for Arrhythmias and Impaired Aerobic Capacity in Tetralogy of Fallot$562,953
R01 · FY2024 · HL · contact PI
Clinical benefits and mechanism of action of angiotensin-II receptor blocker on Cardiovascular remodeling in patients with repaired coarctation of aorta$695,285
R01 · FY2023 · HL · contact PI
Mechanisms of Clinical and Hemodynamic Response to Pulmonary Vasodilator Therapy in Fontan physiology$639,980
R01 · FY2023 · HL · contact PI
Pathophysiologic Mechanism for Arrhythmias and Impaired Aerobic Capacity in Tetralogy of Fallot$568,578
R01 · FY2023 · HL · contact PI
Mechanisms of Clinical and Hemodynamic Response to Pulmonary Vasodilator Therapy in Fontan physiology$632,301
R01 · FY2022 · HL · contact PI
Pathophysiologic Mechanism for Arrhythmias and Impaired Aerobic Capacity in Tetralogy of Fallot$572,851
R01 · FY2022 · HL · contact PI
Pathophysiologic Mechanism for Arrhythmias and Impaired Aerobic Capacity in Tetralogy of Fallot$592,231
R01 · FY2021 · HL · contact PI
Ventricular and Pulmonary Vascular Reserve after the Fontan Operation$173,275
K23 · FY2021 · HL · contact PI
Ventricular and Pulmonary Vascular Reserve after the Fontan Operation$173,275
K23 · FY2020 · HL · contact PI
Ventricular and Pulmonary Vascular Reserve after the Fontan Operation$173,275
K23 · FY2019 · HL · contact PI
Ventricular and Pulmonary Vascular Reserve after the Fontan Operation$173,275
K23 · FY2018 · HL · contact PI